[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overweight-bmi-gt-25\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overweight-bmi-gt-25":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,80,116,143,184,211,237,263,296],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100607851","phase-2-investigation-of-the-efficacy-of-a-probiotic-mixture-in-moderate-metabolic-dysfunction-associated-steatotic-liver-disease-masld-a-mechanistic-trial-100607851",false,"NCT07193927","Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial","Investigation of the Efficacy of a Probiotic Mixture in Subjects With Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial","Inclusion Criteria:\n\n* Patients aged from 18 to 75 years old\n* BMI 25 - 42kg\u002Fm2\n* Diagnosed with MASLD and CAP value \\> 268 dB\u002Fm evaluated by FibroScan®\n* High ALT levels (\\>30 U\u002FL in males and \\>19 U\u002FL in females)\n* Having at least three of the following features compatible with metabolic syndrome:\n\n  i. Waist circumference ≥ 102 cm in males and ≥ 88 cm in females. ii. Fasting serum glucose (≥ 5.6 mmol\u002FL or 100 mg\u002Fdl). iii. Glycated haemoglobin (HbA1c ≥ 5.7%\u002F 39 mmol\u002FL). iv. Diagnosed or treated for type 2 diabetes. v. High blood pressure (≥ 130\u002F85 mmHg). vi. High plasma triglycerides (≥ 1.70 mmol\u002FL or 150 mg\u002Fdl). vii. Lower plasma of High-Density Lipoprotein (HDL cholesterol) (≤ 1.0 mmol\u002FL or 40 mg\u002Fdl for males and ≤ 1.3 mmol\u002FL or 50 mg\u002Fdl for females).\n* Stable weight in the last 3 months (less than ± 4% weight variation).\n* Stable medication or intake of food supplements for a medical condition that can affect study outcomes according to the Investigator's judgement in the last three months prior to study entry (bile salt sequestrants are not permitted).\n* Not planning to change their dietary and lifestyle habits during the study.\n* Willing and able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Fibrosis scores equal or higher than F2 (≥ 8.0 kPa).\n* History of acute or chronic hepatitis A, B or C, autoimmune hepatitis, drug-induced liver diseases, severe liver diseases.\n* Prior or pending liver transplantation.\n\nPatients with at least one of the following concurrent conditions:\n\ni. Type I diabetes ii. Uncontrolled type II diabetes (HbA1c \\>8%) iii. Hypertriglyceridemia \\> 350mg\u002Fdl iv. Human Immunodeficiency Virus (HIV) infection v. Diagnosis of hemochromatosis\n\n* Current use of pioglitazone, SGLT-2 inhibitors, or approved drugs for MASLD or steatohepatitis within 8 weeks.\n* Current use of bile salt sequestrants within 8 weeks.\n* Significant gastrointestinal disease, such as inframmatory bowel disease (IBD, short bowel syndrome, chronic or recurrent diarrhoea, coeliac condition.\n* Pancreatic failure, biliary dysfunction (including cholecystectomy and blood bilirubin abnormalities)\n* Thyroid dysfunction, as assessed by the investigator (clinical criteria)\n* History of:\n\n  i. Cardiovascular disease (ischemic heart disease, heart failure, cerebrovascular disease, periphreal vascular disease).\n\nii. Cancer or immunosuppression. iii. Gastrointestinal surgery in the previous year (with the exception of appendicitis).\n\n* Patients with a history of chronic alcohol or drug abuse: \\> 14 units\u002Fweek for females and \\> 21 units\u002Fweek for male\n* Chronic and heavy smoking (\\>20 cigarettes a day)\n* Regular intake (\\> 3 days\u002Fweek) of other probiotics (including food complements or diary foods with other probiotic strains, e.g. Activia®, Actimel® or similar).\n* Intake of nutraceuticals with an effect on hepatic function such as \\> 500 mg\u002Fday omega-3 fatty acids, high-dose vitamin E supplements or milk thistle (sylibum marianum) extract ot their active ingredients (silymarin, silybin) regularly (\\> 7 days) in the 15 days before study entry.\n* Current use of systemic corticosteroids, androgens, clopidogrel, digoxin, acenocoumarol, warfarin, phenytoin, topiramate, lithium, tricyclic antidepressants, MAOIs or second-generation antipsychotics, amiodarone, tamixofen and\u002For diltiazem.\n* History of use (\\> 3 days) of oral or parenteral antibiotics one month before the study initiation.\n* Chronic use of laxatives.\n* Debilitating illnesses (advanced liver or kidney disease, severe depression, psychotic symptoms, neurological diseases).\n* Current pregnancy (positive urine test) or planning to become pregnant during the study.\n* Breastfeeding at the time of eligibility assessment.\n* Patients who have participated in a clinical trial in the six-month period before the study.","ALL","18 Years","75 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to evaluate whether a specific probiotic mixture can improve liver health in adults with moderate metabolic dysfunction-associated steatotic liver disease (MASLD).\n\nThe main questions it aims to answer are:\n\nCan the probiotics improve liver fat and stiffness as measured by non-invasive imaging (FibroScan® CAP and FAST scores)? Does the probiotic affect other health markers like cholesterol, blood sugar, inflammation, and gut bacteria?\n\nResearchers will compare people taking the probiotic to those taking a placebo (a capsule with no active ingredients) to see if the probiotic has beneficial effects.\n\nParticipants will:\n\nBe randomly assigned to take either the probiotic or placebo daily for 6 months.\n\nAttend 3 study visits (at the start, 3 months, and 6 months). Provide blood and stool samples. Undergo liver scans (FibroScan®). Complete a health and nutrition questionnaire.\n\nThis study includes adults aged 18-65 with moderate MASLD and certain metabolic health conditions. Participants must not be pregnant, breastfeeding, or taking certain medications or supplements that could interfere with the study.",[27,28,29],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Fatty Liver Disease, Nonalcoholic","Overweight (BMI > 25)","RECRUITING","2026-04-29",{"date":33,"type":34},"2026-04-30","ACTUAL",{"date":36,"type":34},"2026-03-20",{"date":38,"type":21},"2027-06-01",{"name":40,"class":41},"AB Biotics, SA","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":63,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":42},"100598614","probiotic-impact-on-cognitive-performance-and-metabolic-outcomes-in-overweight-young-adults-with-impaired-glucose-regulation-100598614","NCT07073781","Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation","A Double-blind Placebo-controlled Exploratory Trial to Assess the Impact of Daily Lab4P Probiotic Supplementation on Cognitive Performance and Metabolic Regulation in Overweight Young Adults With Impaired Glucose Regulation","ProCog","Inclusion Criteria\n\n* Aged 18-40 years\n* Body Mass Index (BMI) between 25.0 and 29.9 kg\u002Fm² (classified as overweight)\n* In good general health (self-reported)\n* Normal self-reported sleep patterns, with no history of diagnosed sleep disorders\n* Willing and able to provide informed consent\n* Able to comply with study procedures, including fasting and oral glucose tolerance testing\n\nExclusion Criteria:\n\n* Diagnosed diabetes (any type).\n* Diagnosed sleep disorders.\n* Fasting glucose \\>6.9 mmol\u002FL during screening.\n* History of bariatric surgery (e.g., gastric bypass, sleeve gastrectomy).\n* Major surgery, significant illness, trauma, infection, or myocardial infarction within the past 6 weeks.\n* Current use of medications affecting glucose metabolism or probiotics\n* Pregnancy or actively trying to conceive\n* Night shift work within the past month","40 Years",{"count":53,"type":21},70,[55],"NA","This 12-week, double-blind, placebo-controlled trial will examine whether daily supplementation with the Lab4P probiotic can improve cognitive performance and metabolic health in overweight adults aged 18 to 40 with impaired glucose tolerance, a preclinical condition where blood glucose regulation is mildly disrupted. Seventy participants will be randomly assigned to receive either Lab4P or a placebo. The study will assess changes in memory, executive function, and processing speed, along with blood glucose control, cardiovascular function, cholesterol levels, body composition, and markers of inflammation. The study will also analyse changes in the gut microbiome and evaluate the safety and tolerability of the probiotic.",[58,59,60,29,61,62],"Impaired Glucose Regulation","Impaired Glucose Tolerance (Prediabetes)","Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)","Cognitive Dysfunction","Neurovascular Coupling Mechanism and Cognitive Function",[64,65,66,67,68,69],"Probiotic supplementation","Psychobiotic","Cognitive performance","Metabolic function","Impaired glucose tolerance","Gut-brain axis","2026-03-25",{"date":72,"type":34},"2026-03-31",{"date":74,"type":34},"2025-08-15",{"date":76,"type":21},"2026-08-20",{"name":78,"class":79},"Leeds Beckett University","OTHER",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":16,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":92,"conditions":93,"keywords":100,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":42},"100619092","pistachio-snacking-and-metabolic-flexibility-100619092","NCT07340125","Pistachio Snacking and Metabolic Flexibility","Effects of Pistachio Snacking on Metabolic Flexibility in Healthy Overweight and Obese Adults","Inclusion Criteria:\n\n* Males and Females\n* Age: 25-45 years\n* Overweight or obese (BMI=25.0-34.9 kg\u002Fm²)\n* Poor sleep quality (Pittsburgh Sleep Quality Index ≥ 5)\n* Healthy (no diagnosed metabolic, cardiovascular, sleep, or other health condition that may significantly alter metabolism, sleep, or ability to participate in the exercise test)\n* Not meeting weekly physical activity recommendations (\\\u003C150 min moderate-intensity exercise, \\\u003C75 minutes of vigorous-intensity exercise, and \\\u003C2 days of strength training)\n* Not following a diet that is restrictive or eliminates certain food group\u002Ftypes\n\nExclusion Criteria:\n\n* Allergies to nuts, especially tree nuts\n* Has a pacemaker\n* Following a diet that is restrictive or eliminates certain food group\u002Ftypes\n* Self-repoted health or disease state that may influence study outcomes, including known metabolic or endocrine disorder (e.g. prediabetes, type 1 or type 2 diabetes, or polycystic ovary syndrome), cardiovascular diseases, neuromuscular disorders, musculoskeletal disorders; current or recent history of cancer\u002Fcancer treatment (within the past year)\n* History of gastrointestinal surgery, hysterectomy\n* For women: pregnant or thinking of becoming pregnant during the time of participation, pregnant within the last year, currently breastfeeding, or known to be perimenopausal",true,"25 Years","45 Years",{"count":20,"type":21},[55],"The purpose of this study is to evaluate the effects of pistachio snacking on metabolic flexibility (at rest, during exercise, and in post-exercise recovery) in healthy overweight and obese adults. Secondary goals include evaluating effects on changes in diet quality, sleep characteristics, physical activity, and hormonal health in women. In randomized order, participants will complete four days of pistachio snacking and four days of normal dietary habits (control). For both conditions, primary outcomes of resting substrate metabolism, metabolic flexibility during exercise, and post-exercise substrate metabolism will be measured pre-post intervention via indirect calorimetry. Secondary outcome of diet quality (kcal, carb, fat, protein) will be measured pre-post intervention via diet log. Exploratory outcomes of daily physical activity (steps, intensity), nightly sleep characteristics (quantity, quality, latency, efficiency), and daytime sleepiness and hunger.",[29,94,95,96,97,98,99],"Obese But Otherwise Healthy Participants","Overweight or Obese","Obese Patients (BMI ≥ 30 kg\u002Fm²)","Poor Sleep Quality","Healthy Participants","Physically Inactive",[101,102,103,104,105,106],"Pistachio","Tree Nuts","metabolic flexibility","metabolism","diet quality","snacking","2026-01-05",{"date":109,"type":34},"2026-01-14",{"date":111,"type":34},"2025-09-01",{"date":113,"type":21},"2026-12-31",{"name":115,"class":79},"University of South Carolina",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":87,"sex":16,"minAge":123,"maxAge":89,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":42},"100608076","redox-status-and-exercise-training-induced-adaptations-100608076","NCT07196852","Redox Status and Exercise Training-induced Adaptations","Effects of N-acetylcysteine on Biological Responses to High-intensity Interval Training in Adults With Overweight\u002FObesity","Inclusion Criteria:\n\n* BMI 25-35 kg\u002Fm2\n* Free of musculoskeletal injuries\n* Free of chronic non-communicable diseases\n* Do not receive any drug therapy\n* Do not receive dietary supplements\n* Normal menstrual cycle (for females)\n* Non smokers\n\nExclusion Criteria:\n\n* NAC intolerance\n* Bleeding disorders\n* Kidney disease\n* Asthma\n* Usage of blood thinners and\u002For angina medication","30 Years",{"count":20,"type":21},[55],"Excess fat accumulation is a key feature of overweight and obesity that is mainly driven by nutrient overload and insufficient physical activity. White adipose tissue displays lipid overload and hypertrophy accompanied by macrophages infiltration, hypoxia, inflammation and excess production of reactive oxygen species (ROS). An inflammatory response and ROS production are also evident in other metabolism regulating tissues and organs such as skeletal muscle, liver, pancreas and hypothalamus, contributing to a chronic inflammatory state, redox status disturbances and metabolic complications. There is overwhelming evidence showing that adults with overweight\u002Fobesity exhibit lower glutathione (GSH) levels in blood erythrocytes, skeletal muscle cells and subcutaneous and visceral adipose tissue cells. GSH, a tripeptide consisting of the amino acids glutamate, cysteine and glycine, is the most abundant thiol-containing antioxidant in the human body and has been, recently, characterized as a novel therapeutic target for the treatment of numerous chronic diseases, due to its potent intracellular redox buffering capacity. Interestingly, lower GSH levels have been associated with diet-induced weight loss resistance, while enhancement of GSH levels through N-acetylcysteine (NAC) supplementation reduces markers of oxidative stress, inflammation, insulin resistance, hypertension, endothelia dysfunction and improves vitamin D metabolism. NAC is a thiol donor that elicits antioxidant effects by (i) directly scavenging ROS and (ii) providing reduced cysteine through deacetylation, which supports the biosynthesis of endogenous GSH via the activity of γ-glutamylcysteine synthase. The aim of this study is to investigate whether NAC supplementation can enhance the exercise training-induced improvements on physical fitness and metabolic health in adult men and women with overweight\u002Fobesity.",[29,128],"Obesity",[130,131,132,133],"overweight","obesity","N-acetylcysteine","high-intensity interval training","2025-12-09",{"date":136,"type":34},"2025-12-16",{"date":138,"type":34},"2025-09-22",{"date":140,"type":21},"2026-12-30",{"name":142,"class":79},"University of Thessaly",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":87,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":161,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":42},"100612570","follow-up-study-of-varapodio-trial-effect-of-longevity-and-fasting-mimicking-diet-on-risk-factors-age-correlated-and-biomarkers-of-aging-100612570","NCT07255300","Follow up Study of Varapodio Trial: Effect of Longevity and Fasting Mimicking Diet on Risk Factors Age Correlated and Biomarkers of Aging","Follow up Study of the Effects of the Longevity and the Fasting Mimicking Diet on Body Composition, Age-related Risk Factors and Biomarkers of Aging in a Randomized Study 1 and 2","Inclusion Criteria:\n\nSubjects of 30-65 years of age;\n\nExclusion Criteria:\n\nindividuals with a family member already included in the study; individuals who are allergic to tree nuts (macadamia, cashew, almond, pecan), soy, oats, sesame, or celery\u002Fceleriac; pregnant females; Individuals with any documented cancer diagnosis within the past 5 years; documented myocardial infarction within past 5 years; documented cerebrovascular accident within past 5 years; chronic steroid use (longer than 45 consecutive days); insulin-dependent diabetes mellitus; individuals taking insulin or insulin-like drugs and individuals taking hypoglycemic agents other than metformin. In this last case, close attention will therefore be paid to the self-monitoring of blood glucose during the FMD cycles; Individuals with severe hypertension (systolic greater than 200 mmHg and or diastolic greater than 105 mmHg.\n\nChange in prescription medications, over-the-counter (OTC) medications, medical foods, and nutritional supplements within 30 days prior to the start and for the duration of the study.\n\nUse of medications classified as narcotics 15 days prior start and for the duration of the study.\n\nUse of prescription medications and\u002For over-the-counter medications for acute and semi- acute medical conditions 15 days prior to start and for the duration of the study.\n\nUse of acetaminophen is permitted on an as-needed basis. Use of an investigational drug or participation in an investigational study within 30 days prior to the start and for the duration of the study.\n\nUse of oral or injectable corticosteroids within 30 days prior to the start and for the duration of the study.\n\nUse of anticoagulant medications (heparin compounds or warfarin) within 30 days prior to the start and for the duration of the study. Use of aspirin 81 mg or 325 mg once daily is permitted.\n\nUse of neuroactive prescription medications including major and atypical antipsychotic medications, anti-depressants, anti-anxiolytics, and epilepsy medications within 30 days prior to the start and for the duration of the study.\n\n(subjects will not be allowed to discontinue prohibited prescription medications to meet enrolment criteria).\n\nA history of allergy or intolerance to study products. Detailed descriptions of study product are included in Section 4.1 and 4.2, appended to the Study Informed Consent.\n\nClinically significant vital sign abnormalities (systolic blood pressure \\\u003C90 mmHg or \\>200 mmHg, diastolic blood pressure \\\u003C50 mmHg or \\>105 mmHg or resting heart rate of \\\u003C50 or \\>100 bpm) at screening visit.\n\nA serious, unstable illness including cardiac, hepatic, renal, gastrointestinal, respiratory, endocrinologic, neurologic, immunologic, or hematologic disease.\n\nKnown infection with HIV, TB or Hepatitis B or C.\n\nA current diagnosis or personal history of:\n\nAny cardiovascular disease including myocardial infarction, angina, cardiovascular surgery (within 5 years), congestive heart failure, cardiac arrhythmias or conduction abnormalities, cerebrovascular accident, transient ischemic attack (TIA), or peripheral vascular disease, deep vein thrombosis or pulmonary embolus. Diabetes mellitus requiring inhaled or injected insulin.\n\nAny autoimmune disease such as inflammatory bowel disease (including Crohn's disease and\u002For ulcerative colitis), multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, polymyositis, scleroderma and\u002For thyroiditis.\n\nAny significant liver or kidney disease such as cirrhosis or non-alcoholic fatty liver disease, glomerulonephritis, and\u002For ongoing dialysis treatment.\n\nAny malignancy (with the exception of adequately treated malignancies with no known recurrence for \\>2 years).\n\nAny serious mental illness including a history of attempted suicide. Any medical condition that in the opinion of the primary care doctor or a specialist would preclude safe participation in this study or interfere with compliance.\n\nUse of drugs of abuse (such as marijuana, cocaine, phencyclidine \\[PCP\\] and methamphetamine) 15 days prior to Day 1 and for the duration of the study.\n\nHistory of regular intake of \\>14 alcoholic drinks per week for females, and \\>21 drinks per week for males (1 drink = 35 cl. beer, 12 cl. wine, or 30 ml. hard liquor).\n\nTechnical reasons\n\nAny condition in which bioelectrical impedance testing would be impossible or uninterpretable (e.g. prostheses in extremities on both sides, limb amputation, implanted pacemaker, inability to lay still or supine, or skin defects on preferred electrode placement sites.\n\nOther Exclusion Criteria: Inability to comply with study and\u002For follow-up visits.\n\nAny concurrent condition (including clinically significant abnormalities in medical history, physical examination or laboratory evaluations) which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.\n\nAny sound medical, psychiatric and\u002For social reason which, in the opinion of the PI, would preclude safe participation in this study or interfere with compliance.\n\nAbnormal laboratory findings including: abnormal blood counts (hematocrit \\\u003C 33% or \\> 47%; WBC \\\u003C 3.0 or \\> 12.0 x10\\^3\u002Fmm3; platelets \\\u003C 140 or \\> 500 x 10\\^9\u002FL); abnormal kidney function test (creatinine \\> 2.5 mg\u002FdL) or liver function test(s) (AST, ALT, alkaline phosphatase) \\> 1.5X the upper limit of normal; serum calcium \\> 11 mg\u002FdL); serum K \\\u003C 3.5 mEq\u002FL; Na \\\u003C 134 or \\> 148 mmolL-1 Women of Childbearing Potential Contraception: the effects of the study products on the developing human fetus have not been studied extensively. For this reason, women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential will have a pregnancy test prior to receiving study products. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform study staff and her primary care physician immediately.\n\nPregnancy: because there is an unknown but potential risk for adverse events in pregnant women during treatment with the study products, pregnant women are not eligible for study participation.\n\nBreast-feeding: Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study products, breastfeeding mothers are not eligible for study participation.",{"count":151,"type":21},135,[55],"A large ongoing randomized, open-label trial aimed at evaluating the effects of two different dietary interventions, FMD and LD, on body composition and cardiovascular (CV) biomarkers in a real word population (NCT05698654) is actually ongoing. This trial started in January 2024 will enrol 501 adult subjects between the ages of 30 and 65: 167 subjects randomized to the FMD arm with a 5-day meal program once every three months for a 6-month period (arm 1); 167 subjects randomized to follow the FMD plus a Longevity Diet program (FMD+LD) for a 6-month period (arm 2); 167 randomized to the control group (arm 3) that will continue their usual diet. On 2024,410, participants were enrolled and randomly assigned to FMD, FMD + LD, or control arm. Although preliminary data demonstrated the beneficial effects of such nutritional plans on body weight, BMI, body composition, and cardiovascular (CV) biomarkers, limited data is available on the long-term effects of these powerful nutritional interventions.",[155,156,157,158,29,159,160],"Fat Mass","Risk Factors Cardiovascular Disease","Epigenetic Aging","Metabolism Changes","Risk Behavior","Obesity (Disorder)",[162,163,164,165,166,167,168,169,170,171,172,173,174,155],"fasting","fasting mimicking diet","Longevity Diet","Longevity","Diet","Aging","FMD","Nutrition","Diseases","LD","Clinical Trial","Randomized","Health","2025-11-20",{"date":177,"type":34},"2025-12-01",{"date":179,"type":34},"2025-05-02",{"date":181,"type":21},"2027-06-02",{"name":183,"class":79},"Fondazione Valter Longo",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":87,"sex":16,"minAge":17,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":42},"100586186","early-phase-1-l-acidophilus-strain-tw01-on-gut-health-body-composition-and-inflammation-100586186","NCT06912100","L. Acidophilus (Strain TW01) on Gut Health, Body Composition, and Inflammation","A Pilot Study of the Probiotic L. Acidophilus (Strain TW01) on Gut Health, Body Composition, and Inflammation","Inclusion Criteria:\n\n1. Age 18-60 years\n2. Body mass index (BMI) between 28 kg\u002Fm2 and 40 kg\u002Fm2\n3. Waist circumference ≥ 88 cm or 35 inches for women, ≥ 102 cm or 40 inches for men\n4. Willing to consume experimental capsules daily\n5. Willing to prepare and consume the delivered meal kits\n6. Do not fit any exclusion criteria\n\nExclusion Criteria:\n\n1. Self-reported history of immunodeficiency, major gastrointestinal surgery, renal or liver disease, diabetes, heart disease, stroke, peripheral artery\u002Fvascular disease, cancer, eating disorders, gut-associated pathologies, autoimmune diseases, pacemaker, thyroid disease, gallbladder disease, chronic inflammatory diseases, scleroderma, blood clotting disorders, intravenous drug use\n2. Weight changes \\> 10% over the last 4 weeks\n3. Oral antibiotics and\u002For probiotics use up to 1 month prior to study and during study\n4. Currently taking GLP-1 analogues (e.g., Ozempic), anti-inflammatory medications (e.g., corticosteroids), daily use of nonsteroidal anti-inflammatory drugs (NSAIDs) (occasional use is permitted), medications which primarily affect blood clotting (e.g., warfarin), or any medications that suppress the immune system.\n5. Dairy allergy\n6. Currently pregnant or breast-feeding","60 Years",{"count":193,"type":21},12,[195],"EARLY_PHASE1","This is a pilot research study to investigate the effects of a probiotic supplement (L. acidophilus, strain TW01) on substances found in the stool and bloodstream, gut bacteria composition, body composition, as well as any relationship of these substances with markers of inflammation. Lactobacillus acidophilus is commonly found in a variety of fermented foods, including yogurt, cheese, and kefir, due to its ability to produce lactic acid and other substances. This bacterium is generally well-tolerated in healthy individuals and has a longstanding history of safe use. The investigators are doing this pilot study to see if a particular probiotic, called L. acidophilus (strain TW01) and isolated from fermented coffee grounds, can make a positive difference in human gut and overall health. Specifically, the investigators want to look at how this probiotic affects certain substances in human stool and blood, the makeup of the bacteria in the gut, and aspects of body composition. The investigators are also interested in whether these changes relate to markers of inflammation, which can tell us more about their impact on overall health. This probiotic strain has been shown in other studies to be safe and well tolerated, and the investigators hope our research will help us better understand how it works and whether it might support health in humans.",[29,198],"Obese, Otherwise Healthy Volunteers",[131,200,201],"probiotics","gut health","2025-07-22",{"date":204,"type":34},"2025-07-25",{"date":206,"type":34},"2025-07-01",{"date":208,"type":21},"2027-12",{"name":210,"class":79},"University of Connecticut",{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":87,"sex":16,"minAge":17,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":222,"briefSummary":223,"conditions":224,"keywords":225,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":42},"100595688","prevent-and-reverse-obesity-in-children-adolescents-and-young-adults-100595688","NCT07035704","Prevent and Reverse Obesity in Children, Adolescents and Young Adults","De-Risking Metabolic, Environmental and Behavioral Determinants of Obesity in Children, Adolescents and Young Adults","PasGras","Inclusion Criteria:\n\n* 18-55 years old overweight or obese men and women (BMI ≥ 25 kg\u002Fm2).\n* Signed informed consent.\n* Have a mobile phone, tablet, or computer with internet access.\n\nExclusion Criteria:\n\n* Waist circumference \\> 150 cm\n* Suffer from diabetes or other disorders of glucose metabolism\n* Suffer from dyslipidemia or other alterations of lipid metabolism (LDL cholesterol ≥ 189 mg\u002FdL and\u002For triglycerides ≥ 350 mg\u002FdL).\n* Present chronic gastrointestinal problems such as Crohn's disease or irritable bowel syndrome.\n* Present any chronic or autoimmune disease in clinical manifestation such as hepatitis, hyper or hypothyroidism or metabolic diseases.\n* Have a diagnosed liver disease other than steatotic liver disease.\n* Taking supplements or multivitamin supplements or phototherapeutic products for weight loss that interfere with the study.\n* Have taken antibiotics in the last 30 days.\n* Follow a low-calorie diet and\u002For pharmacological treatment for weight loss.\n* Being a smoker.\n* Regular alcohol consumption (more than 4 Standard Drink Units (SDU) per day or 28 SDU per week.\n* Have lost more than 3 kg of weight in the last 3 months.\n* Suffering from eating disorders or psychiatric disorders.\n* Present food intolerances and\u002For allergies related to the study products, such as allergy to edible mushrooms or fungal spores or to any of the components of the Lebanese herbal mixture Za'atar such as sesame seeds.\n* Be pregnant or intend to become pregnant or be breastfeeding,\n* Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study.\n* No or limited access to the Internet.","55 Years",{"count":221,"type":21},200,[55],"Obesity and overweight are non-communicable diseases with an increasing incidence in children, adolescents, and adults. International efforts to reverse the current epidemiological trend of rising overweight, obesity, and related diseases have so far been insufficient to achieve this goal. Therefore, a change in strategy-both at the individual and public health levels-is urgently needed.\n\nSearching the litterature, there are currently no studies employing a comprehensive, personalized, and multi-level strategy to induce stable changes in dietary and lifestyle habits, while also conducting careful follow-up of outcomes and exploring the pathogenic mechanisms affecting metabolic pathways, pro-inflammatory and systemic conditions, and intestinal permeability in overweight and obese patients.\n\nEvidence shows the beneficial effects of specific dietary patterns (e.g., the Mediterranean Diet) and a healthy lifestyle in reducing body\u002Forgan fat accumulation. However, a comprehensive evaluation of their effects-particularly following personalized strategies and careful follow-up-on the pathogenic mechanisms influencing cardiovascular and metabolic risk, pro-inflammatory status, and intestinal permeability in the medium-to-long term is still lacking.",[29],[226],"MeD diet, Healthy life, obesity","NOT_YET_RECRUITING","2025-06-20",{"date":230,"type":34},"2025-06-25",{"date":232,"type":21},"2025-09-15",{"date":234,"type":21},"2027-03-30",{"name":236,"class":79},"piero portincasa",{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":87,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":247,"phases":4,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":4},"100589901","mapping-obesity-related-subtypes-and-interconnected-clusters-100589901","NCT06960434","Mapping Obesity-related Subtypes And Interconnected Clusters","Systemic Interpretation of Personal and Environmental Characteristics in Overweight and Obesity: From Data Patterns to Practical Interventions","MOSAIC","Inclusion Criteria:\n\n* researchers or professionals with expertise in obesity, lifestyle, environment, psychosocial or medical factors;\n* experience in data interpretation and\u002For public health;\n* able to communicate in Dutch;\n* willing to participate in the online survey and\u002For expert panel meeting\n\nExclusion Criteria:\n\n* no relevant domain expertise;\n* inability to give informed consent",{"count":246,"type":21},15,"OBSERVATIONAL","In the Netherlands, about half of all adults are currently living with overweight. This number is expected to rise to as much as 64% by the year 2050, especially among younger adults aged 18 to 44. Overweight and obesity increase the risk of chronic conditions such as heart disease, diabetes, and joint problems. However, there is no single cause behind these issues. Instead, they result from a complex combination of factors - including nutrition, physical activity, sleep, stress, income, environment, and even air quality. These factors often influence each other and vary from person to person.\n\nThis study aims to better understand these patterns and connections. By analyzing large sets of data, researchers are identifying different subtypes of people with overweight or obesity. These subtypes reflect groups of individuals who share similar personal, lifestyle, and environmental characteristics. Understanding these differences makes it possible to develop more personalized lifestyle advice and support. That way, care and prevention efforts can be better tailored to what people actually need and what works best for them in practice. Experts from various fields are helping interpret the results, so that scientific insights can be translated into practical solutions for individuals, communities, and healthcare settings.",[128,29],[130,131,251,252,253,254],"prevention","lifestyle","data-driven","clusters","2025-04-28",{"date":257,"type":34},"2025-05-07",{"date":259,"type":21},"2025-05-01",{"date":111,"type":21},{"name":262,"class":79},"Zuyd University of Applied Sciences",{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":273,"briefSummary":274,"conditions":275,"keywords":277,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100589151","impact-of-protein-supplementation-and-resistance-training-on-body-composition-functional-parameters-metabolic-adaptation-and-nitrogen-balance-in-adults-aged-45-years-and-older-with-overweight-or-obesity-receiving-incretin-based-medications-100589151","NCT06950684","Impact of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults Aged 45 Years and Older With Overweight or Obesity Receiving Incretin-based Medications","The Effect of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults (Aged ≥45 Years) With Overweight\u002FObesity Receiving Incretin-Based Weight Loss Medication for 6 Months: A Multicenter RCT","PRIME","Inclusion Criteria:\n\n* Adults aged ≥45 years.\n* Overweight or obese (BMI ≥30, or BMI ≥27 with at least one obesity-related comorbidity).\n* Eligible to receive incretin-based weight loss medications (e.g. Wegovy or Mounjaro).\n* Able to read and speak Hebrew fluently.\n\nExclusion Criteria:\n\n* Medical contraindications for incretin-based weight-loss medications.\n* Current treatment with insulin or sulfonylurea medications.\n* Inflammatory bowel disease.\n* Active or unstable psychiatric disorders or cognitive impairment.\n* Active bulimia nervosa.\n* Previous bariatric surgery or bariatric endoscopic procedures.\n* Use of other weight management medications within the past month.\n* Weight loss of ≥5% within the past three months.\n* Implanted cardiac pacemaker or other electronic implants.\n* Regular resistance training within the past three months.\n* Regular use of protein supplements.\n* Allergy or intolerance to dairy proteins or vegan lifestyle.",{"count":272,"type":21},180,[55],"This study aim to evaluate the effects of protein supplements and resistance training on body composition, functional parameters, metabolic adaptation, and nitrogen balance in adults (aged ≥45 years) with overweight\u002Fobesity receiving weekly Incretin-Based obesity management medication treatment for 6 months.\n\nA parallel design, open-label, multicenter randomized controlled trial will be conducted among 240 patients (aged ≥45 years) initiating Incretin-Based obesity management medication. Participants will be recruited through obesity clinics at the Tel-Aviv Sourasky Medical Center and the Tel-Aviv Assuta Medical Center, obesity clinics of HMOs, and social media groups. They will be randomly assigned to one of two groups in a 1:1 ratio: protein supplements ('Easy Whey' 25 gr protein\u002Fday) plus weekly resistance training and no intervention. Data will be collected at baseline, 3, and 6 months, including demographics, medical status, body composition, functional parameters, resting metabolic rate, nitrogen balance, and physical activity performance.\n\nAll participants will be advised to follow an exercise regime, a reduced-calorie diet based on the principle of the Mediterranean eating pattern and be encouraged to follow a regular meeting schedule with a registered dietitian.",[128,29,276],"Weight Loss",[278,279,280,281,282,283,284,285,286,287],"Protein supplementation","Resistance training","Body composition","Metabolic rate","Nitrogen balance","Incretin-based medications","Wegovy","Mounjaro","Older adults","Obesity treatment","2025-04-27",{"date":290,"type":34},"2025-04-30",{"date":206,"type":21},{"date":293,"type":21},"2028-07-01",{"name":295,"class":79},"Assuta Medical Center",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":87,"sex":16,"minAge":302,"maxAge":51,"enrollmentInfo":303,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":300,"conditions":306,"keywords":4,"overallStatus":227,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":4},"100588929","the-effect-of-motivational-interviewing-on-anthropometric-measurements-eating-attitudes-and-cardiometabolic-index-in-overweight-and-obese-patients-100588929","NCT06947798","The Effect of Motivational Interviewing on Anthropometric Measurements, Eating Attitudes, and Cardiometabolic Index in Overweight and Obese Patients","Inclusion Criteria:\n\n* Body Mass Index (BMI) in the range of 25 to 34.9 kg\u002Fm² was considered as an inclusion criterion\n* Being between 20 and 40 years of age (corresponding to the young adulthood period according to Erikson)\n\n  \\-- Participants were required to be registered with the Saltuklu Family Health Center.\n* Willingness to participate in the study and provision of informed consent were required\n\nExclusion Criteria:\n\n* Current use of medications known to induce weight gain or loss\n* Presence of a diagnosed chronic illness\n* Pregnancy or being in the lactation period.\"","20 Years",{"count":304,"type":21},80,[55],[307,308,128,29,309,310],"Motivational Interviewing","Cardiometabolic Index","Anthropometric Measurements","Eating Behavior Disorders","2025-04-24",{"date":288,"type":34},{"date":314,"type":21},"2025-05",{"date":316,"type":21},"2025-08",{"name":318,"class":79},"Saltuklu Aile Sağlığı Merkezi"]